Technical Analysis for ALT - Altimmune, Inc.

Grade Last Price % Change Price Change
C 7.20 8.27% 0.55
ALT closed up 8.27 percent on Monday, July 1, 2024, on 1.11 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Crossed Above 20 DMA Bullish 8.27%
Calm After Storm Range Contraction 8.27%
Inside Day Range Contraction 8.27%
Wide Bands Range Expansion 8.27%
20 DMA Resistance Bearish 12.76%
200 DMA Resistance Bearish 12.76%

   Recent Intraday Alerts

Alert Time
200 DMA Resistance about 8 hours ago
50 DMA Resistance about 8 hours ago
Rose Above 50 DMA about 10 hours ago
2x Volume Pace about 10 hours ago
1.5x Volume Pace about 10 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Altimmune, Inc. Description

Altimmune,Inc., formerly Pharmathene, Inc., is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Phosphates Manufacturing Process Obesity Vaccines Reversal Nerve Manufacturing Processes Biodefense Choline Biological Warfare Anthrax Chemical Warfare Cholinesterase Anthrax Vaccines Athene

Is ALT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.84
52 Week Low 2.09
Average Volume 3,722,019
200-Day Moving Average 6.94
50-Day Moving Average 7.10
20-Day Moving Average 6.62
10-Day Moving Average 6.52
Average True Range 0.68
RSI (14) 54.13
ADX 16.33
+DI 30.98
-DI 21.54
Chandelier Exit (Long, 3 ATRs) 6.45
Chandelier Exit (Short, 3 ATRs) 7.68
Upper Bollinger Bands 7.64
Lower Bollinger Band 5.60
Percent B (%b) 0.78
BandWidth 30.88
MACD Line -0.14
MACD Signal Line -0.25
MACD Histogram 0.105
Fundamentals Value
Market Cap 386.85 Million
Num Shares 53.7 Million
EPS -1.54
Price-to-Earnings (P/E) Ratio -4.68
Price-to-Sales 1976.80
Price-to-Book 3.74
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.18
Resistance 3 (R3) 8.10 7.71 8.01
Resistance 2 (R2) 7.71 7.46 7.74 7.96
Resistance 1 (R1) 7.45 7.30 7.58 7.53 7.90
Pivot Point 7.06 7.06 7.12 7.09 7.06
Support 1 (S1) 6.80 6.81 6.93 6.88 6.50
Support 2 (S2) 6.41 6.65 6.44 6.44
Support 3 (S3) 6.15 6.41 6.39
Support 4 (S4) 6.23